Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Viking Global and Axovant Sciences Ltd (AXON)

Page 1 of 17

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Viking Global Investors 0 0 0 75,000,000 75,000,000 69.8%
Viking Global Performance 0 0 0 75,000,000 75,000,000 69.8%
Viking Global Equities 0 0 0 75,000,000 75,000,000 69.8%
Viking Global Equities II 0 0 0 75,000,000 75,000,000 69.8%
VGE III Portfolio Ltd 0 0 0 75,000,000 75,000,000 69.8%
Viking Long Fund GP 0 0 0 75,000,000 75,000,000 69.8%
Viking Long Fund Master Ltd 0 0 0 75,000,000 75,000,000 69.8%
Viking Global Opportunities GP 0 0 0 75,000,000 75,000,000 69.8%
Viking Global Opportunities Portfolio GP 0 0 0 75,000,000 75,000,000 69.8%
Viking Global Opportunities Illiquid Investments Sub-Master 0 0 0 75,000,000 75,000,000 69.8%
O. Andreas Halvorsen 0 0 0 75,000,000 75,000,000 69.8%
David C. Ott 0 0 0 75,000,000 75,000,000 69.8%
Daniel S. Sundheim 0 0 0 0 0 0.0%
Andreas Halvorsen
Andreas Halvorsen
Viking Global

Page 1 of 17 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13D
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934

AMENDMENT NO. 1*

Axovant Sciences Ltd.
(Name of Issuer)
Common Shares, $0.00001 par value
(Title of Class of Securities)
G0750W104
(CUSIP Number)

Eric Komitee

General Counsel

55 Railroad Avenue

Greenwich, Connecticut 06830

203-863-5062

(Name,
Address and Telephone Number of Person

Authorized
to Receive Notices and Communications)

June 12, 2017
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note.
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7
for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 16 Pages)

______________________

* The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Axovant Sciences Ltd.
Trade (AXON) Now!
Page 1 of 17